59 results about "Gastrointestinal Injury" patented technology

The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.

Nitric oxide releasing oxindole prodrugs are described which are useful in methods of treating or preventing pain, inflammation, fever, or gastrointestinal lesions in a patient in need of such treatment, or of modifying an inflammatory disease or condition by favorably affecting the outcome thereof in said patient, wherein there is administered to said patient a therapeutically effective amount of a compound of Formula (I): and pharmaceutically acceptable salts thereof. In preferred embodiments, X is a covalent bond; RA and RB are both hydrogen; n is the integer 4; Y is -O-; Z is -NO2; RC is a member selected from the group consisting essentially of 5-Cl and 5-F; RD is a member selected from the group consisting essentially of 6-Cl and 6-F; and RE is a member selected from the group consisting essentially of benzyl, 2-furyl, 2-thienyl, 5-chloro-2-thienyl and 5-trifluoromethyl-2-thienyl.

The present invention relates to medicine preparation, and is especially one kind of fast releasing solid omerprazole preparation and its preparation process. The present invention combines omerprazole with certain amount of sodium hydroxide, and the medicine preparation can neutralize gastric acid and the medicine may be absorbed effectively. Certain amount of sodium hydroxide can neutralize gastric acid without causing gastrointestinal damage.

The invention discloses a medicine composition for assisting chemotherapeutics and an application of the medicine composition. An effective dose of antrodia camphorata sporocarp extract is obtained by hot water soaking, low polar solvent extraction and other steps and collocated with a pharmaceutically acceptable supporting agent to prepare the medicine composition; the medicine composition can be used for improving a treatment effect of the chemotherapeutics cisplatin and gemcitabine on a cancer; and at the same time, the medicine composition can improve side effects such as hair slipping, muscle degradation and atrophy, gastrointestinal injury and kidney inflammation injury in a process of treating the cancer.

The invention discloses the application of glycyrrhetinic acid derivatives in the preparation process of anti-inflammatory drugs, in particular to the glycyrrhetinic acid derivatives as well as pharmaceutically acceptable salt thereof, drug compositions containing the derivatives and anti-inflammatory action of the drug compositions, wherein, the glycyrrhetinic acid derivatives can release gaseous signal molecule hydrogen sulfide. The invention discloses and provides the glycyrrhetinic acid derivatives that can release gaseous signal molecule H2S, wherein, glycyrrhetinic acid and gaseous signal molecule hydrogen sulfide release groups are coupled through ester bonds or amido bonds so as to obtain the glycyrrhetinic acid derivatives. Pharmacology experimental results show that the glycyrrhetinic acid derivatives achieve remarkable anti-inflammatory action and have no significant gastrointestinal tract injury, and show that the glycyrrhetinic acid derivatives can be used for preparing the drugs for treating various inflammations and related diseases thereof.

The invention discloses a novel gas signal molecule donator and a preparation method and medical use thereof, in particular to a compound with new structure and the preparation method and medical use of the compound. The compound is a compound with a general formula YLXYII or the salt of the compound, comprises the portion related with hydrogen sulfide and is often combined with compounds in covalence mode or forms the salt. Pharmacological results show that the compound has remarkable anti-inflammatory effect and tumor resistance without remarkable damage to gastrointestinal tract, so that the compound can be used for preparing and treating various diseases such as inflammation, cardiovascular diseases, and diseases related with tumor. In addition, the preparation method for preparing the compound is further provided.

The invention relates to the use of a composition comprising extract of Buddleja globosa Hope and pharmacologically accepted excipients for the preparation of a phyto-pharmaceutical agent, a drug or a nutraceutical for the prevention of gastrointestinal disorders, particularly those associated with treatment with nitrofurantoin or gastric disorders produced by ulcers, gastric diseases or damage to the gastrointestinal tract. The aforementioned disorders can correspond to abdominal pain, dyspepsia, nausea, vomiting, diarrhea, constipation, inflammation and cephalalgia resulting from treatment with nitrofurantoin and other antimicrobials. In addition, the extract and the compositions thereof can be used to enhance the antibacterial action of nitrofurantoin, particularly against Escherichia coli.

The invention relates to a cell growth factor gene drug for preventing and/or treating acute stress-related gastrointestinal injury, and use of HIF-1 alpha and KGF genes in preparing drugs for preventing and/or treating acute stress-related gastrointestinal injury diseases. The invention also relates to a pharmaceutical composition comprising HIF-1 alpha and KGF. The growth factor gene drug provided by the invention can beneficially prevent and/or treat acute stress-related gastrointestinal injury diseases.

The present invention provides compositions and methods for treating or preventing gastrointestinal damage associated with acute or chronic non-steroidal anti-inflammatory drug (NSAID) therapy, including, for example, NSAID-induced gastropathy or enteropathy. In various embodiments, the invention relates to administering a regimen of larazotide (or a derivative) to a patient to repair or prevent injury to mucosal tissue of the gastrointestinal epithelium. In accordance with the invention, larazotide functions to repair injured mucosal tissue or prevent injury to mucosal tissue in a patient undergoing acute or chronic NSAID therapy.

The invention discloses a traditional Chinese medicine composition for preventing acute gastrointestinal injury of sepsis which includes coptis, scutellaria, phellodendron, gardenia, peony bark, radix rehmanniae, radix paeoniae rubra, and fructus aurantii. The traditional Chinese medicine composition of this invention can significantly reduce the incidence of acute gastrointestinal injury in sepsis patients, significantly shorten mechanical ventilation and retention time of iCU and lower the 28 day mortality and gastrointestinal attributable mortality. These differences are statistically significant. This medicine can significantly reduce the severity of disease in patients with severe sepsis, relieve illness effectively, improve prognosis and have the advantages of safety without side effects.

The invention relates to blueberry weight losing glue and a preparation method thereof, and belongs to the technical field of paint. The blueberry weight losing glue consists of the following components in parts by weight: 250-500 parts of blueberry powder, 500-750 parts of konjac flour and 3.75-6.25 parts of table salt. The finished product disclosed by the invention is safe and free of any side effect, and a product can be use for solving the problem of a pineapple weight losing product which causes relatively serious gastrointestinal injury and also can avoid injury in human bodies caused by the use of Chinese herbal medicines or hormone products; the product can be used by users selves without the real-time guidance of doctors, and instead of controlling diet, the users can take up nutrients required by human bodies normally; the preparation method disclosed by the invention is simple and reliable, and the prepared product is excellent in performance; and when the product is taken up for 15 days, the weight can be reduced by 7-8kg, so that public demands are met.

Methods of preventing, ameliorating and/or treating radiation induced gastrointestinal tract injury comprising the administration of a therapeutically effective amount of Mesna to a patient are provided. Methods for preventing, treating and/or ameliorating gastrointestinal tract injury induced by radiation therapy, alone or in combination with other therapies for diseases or conditions such as gastrointestinal malignancies, urogenital malignancies, gynecologic malignancies, and osteogenic and other sarcomatous malignancies in which pelvic structures are involved.

A nutritional supplement containing fish oil and selenium has been identified that potentiates radiotherapy of tumors in a synergistic fashion. Cotherapy with such a supplement and radiotherapy results in substantially improved reductions in tumor volume of animal models relative to radiotherapy alone, and reduces common side effects such as weight loss, inflammation, and damage to the gastrointestinal tract. Such cotherapy was also found to reduce the incidence of metastasis from the primary implantation site, and to modulate expression of genes associated with apoptosis in tumor cells. A formulation for such a supplement that is both well tolerated and palatable is also provided.

Disclosed is a method for treating tumor in a mammalian subject, which comprises administering a combination of (a) an anti-tumor agent and (b) a fatty acid derivative represented by the formula (I):

to the subject in need thereof. The application also discloses a method for treating damages, especially gastrointestinal damages including mucositis such as stomatitis induced by an anti-tumor agent, wherein the method comprises administering a fatty acid derivative of formula (I) to the subject who is receiving the anti-tumor agent.